Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cergutuzumab amunaleukin (CEA-IL2v), a monomeric immunocytokine, targets carcinoembryonic antigen (CEA) and is based on an IL-2 variant. It exhibits immunostimulating and antineoplastic activities.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Cergutuzumab amunaleukin (CEA-IL2v), a monomeric immunocytokine, targets carcinoembryonic antigen (CEA) and is based on an IL-2 variant. It exhibits immunostimulating and antineoplastic activities. |
Molecular Weight | N/A |
CAS No. | 1509916-03-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cergutuzumab amunaleukin 1509916-03-3 inhibitor inhibit